Abstract:The nucleotide-binding, oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is a multiprotein complex that combines sensing, regulation, and effector functions to regulate inflammation in health and disease. NLRP3 is activated by a diverse range of inflammation-instigating signals known as pathogen associated molecular patterns and danger associated molecular patterns. Upon activation, NLRP3 oligomerizes and recruits partner proteins to form a supramolecular platform to process the maturation and release of interleukin (IL)-1 β , IL-18, and gasdermin D, major mediators of inflammation and inflammatory cell death termed pyroptosis. The NLRP3 inflammasome has been implicated in the pathogenesis of a wide range of disease conditions, including chronic inflammatory disease that are associated with lifestyle and dietary changes, aging, and environmental exposures, and have become the leading cause of death worldwide. Pharmacological targeting of NLRP3 and signaling demonstrated promising efficacy in ameliorating a list of disease conditions in animal models. These findings underscore the potential and importance of NLRP3 as a druggable target for treating a range of diseases. In this review, recent progress in understanding the structure and mechanism of action of the NLRP3 inflammasome is discussed with focus on pharmacological inhibition of NLRP3 by small molecule inhibitors. New structural and mechanistic insights into NLRP3 activation and inhibitor-NLRP3 interactions would aid in the rational design and pharmacological evaluation of NLRP3 inhibitors for treatment of human disease. Significance Statement The NLRP3 inflammasome plays central role in innate immune sensing and control of inflammation. Pharmacological inhibition of NLRP3 demonstrated promising efficacy in a range of diseases in animal models. Recent elucidation of the structure and inhibitor binding of NLRP3 generated new insights into its mode of action and inhibitor-NLRP3 interaction at molecular levels, providing new framework for developing small chemical inhibitors of NLRP3 with improved efficacy and specificity against chronic disease that has become major health concerns worldwide.

AA467197 Controls the Hyperactivation of the NLRP3 Inflammasome During Infection

NLRP3 Inflammasome Activation Triggers Gasdermin D–independent Inflammation

Activation of GSDME compensates for GSDMD deficiency in a mouse model of NLRP3 inflammasomopathy

Caspase-1 and Gasdermin D Afford the Optimal Targets with Distinct Switching Strategies in NLRP1b Inflammasome-Induced Cell Death

The Inhibitor Effect of RKIP on Inflammasome Activation and Inflammasome-Dependent Diseases

The NLRP3 inflammasome: activation and regulation

Modulatory mechanisms of NLRP3: Potential roles in inflammasome activation

Recent Insights into the Regulatory Networks of NLRP3 Inflammasome Activation

Β-Arrestin1 is Critical for the Full Activation of NLRP3 and NLRC4 Inflammasomes

The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors

The NLRP3 inflammasome: molecular activation and regulation to therapeutics

Small molecule inhibitor binds to NOD-like receptor family pyrin domain containing 3 and prevents inflammasome activation

AKT Controls NLRP3 Inflammasome Activation by Inducing DDX3X Phosphorylation

Fantastic voyage: The journey of NLRP3 inflammasome activation

Small molecule inhibitor binds to NLRP3 and prevents inflammasome activation

Gasdermin D is an Executor of Pyroptosis and Required for Interleukin-1Β Secretion

A novel Nlrp3 knock-in mouse model with hyperactive inflammasome in development of lethal inflammation

Atg16l2 augments Nlrc4 inflammasome activation by facilitating NAIPs–NLRC4 association

LNCGM1082 -Mediated NLRC4 Activation Drives Resistance to Bacterial Infection

Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction

SIRT3-mediated deacetylation of NLRC4 promotes inflammasome activation